OH-PROCTER-&-GAMBLE
11.1.2021 16:02:36 CET | Business Wire | Press release
During a time when many things feel out of our control, people have taken stock of their health and are seeking ways to make a meaningful, positive impact – all from the comfort of home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005188/en/
This year, at the 2021 Consumer Electronics Show (CES), Oral-B will highlight its commitment to powering the smallest daily habits, such as using an electric toothbrush, to create the biggest positive impact on the health of your whole body, whole family and the whole planet, through its first ever virtual experience.
Located within P&G’s LifeLab Everyday virtual platform, the virtual experience will highlight Oral-B iO, the brand’s most innovative toothbrush, reimagined and redesigned from the inside out to remove 100% more plaque than a manual toothbrush.
- The unique dentist-inspired round brush head is designed to surround each tooth with its micro-vibrating bristles to reach below the gumline for a deep, professional clean feeling every day.
- The bimodal smart pressure sensor is the first of its kind to provide positive brushing feedback, identifying and guiding users to brush in the optimal pressure range to protect gums and enamel.
- The Linear Magnetic Drive System delivers controlled, consistent movements from the handle to brush tips, producing gentle micro-vibrations for a more enjoyable experience and efficiently transferring more energy directly to the bristle tips.
- The Smart Display with Personalized Brushing Modes offers an intuitive interface that provides coaching and motivation throughout the cleaning process and features up to seven brush modes for a highly personalized experience.
And this all comes together with Artificial Intelligence Tracking via the Oral-B iO App. It provides real-time individual tracking and coaching, thanks to artificial intelligence informed by thousands of recorded brushing sessions. Oral-B iO has a simple and intuitive user interface that guides consumers through a two-minute brushing session with 3D teeth tracking to ensure a professional clean feeling every time.
Recently, Oral-B partnered with Scientific American to further explore and understand the new research and innovations transforming our understanding of the connection between oral health and overall health.
“Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health,” explains Jeremy A. Abbate, VP & Publisher at Scientific American, “Gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”
Those warning signs can be as small as bleeding gums or tooth loss but can lead to more severe conditions such as heightened pregnancy complications, cognitive loss and more than double the risk of cardiovascular disease and diabetes.
In clinical tests, Oral-B iO provided a deeper cleaning of teeth and gums, allowing users to easily and effectively maintain oral health. Oral-B iO users experienced:
- 100 percent healthier gums in just one week, when compared to manual toothbrushes
- 6 times more plaque removal along the gumline, when compared to manual toothbrushes
- 83 percent of gingivitis patients moved from unhealthy to healthy gums in eight weeks
Lisa Ernst, Senior Vice President, Research & Development, Oral Care stated, “An Oral-B electric toothbrush is a powerful first step in being proactive against the risks associated with gum disease. We give consumers the power to take control of their families’ health at home with Oral-B iO, which helps prevent and reduce gingivitis for the best gum health.”
In addition, P&G’s LifeLab Everyday will feature P&G Oral Care’s newest sustainability commitments to advance healthy oral care habits to transform the health of people while reducing our impact on our planet. Healthy habits for the environment mean a world where everyone respects our planet and its natural resources by:
- Turning off the tap when brushing your teeth
- Recycling packaging and products
- Unplugging the toothbrush charger when not in use.
For more information on Oral-B iO, please visit oralb.com .
About Oral-B
Oral-B® is the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand includes manual and electric toothbrushes for children and adults, oral irrigators and interdental products, such as dental floss.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news .
About Procter & Gamble’s LifeLab Everyday:
At P&G’s LifeLab Everyday is a new virtual platform that reveals how innovation at Procter & Gamble is reinventing consumer experiences and making progress toward a better future for our society and our planet. The exhibit combines robust, consumer-based insights with breakthrough science inspired by how people live, work, play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom